Vertex Pharmaceuticals (VRTX)
$291.10 4.82 (1.68%)
19:54 EDT VRTX Stock Quote Delayed 30 Minutes
Previous Close $291.10
Market Cap 74.18B
PE Ratio 338.49
Volume (Avg. Vol.) 1.10M
Day's Range 287.45 - 293.95
52-Week Range 165.23 - 299.21
Dividend & Yield N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
- From InvestorPlace
- From the Web
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
VRTX stock is a biopharmaceutical with an A-Rating that has no stake in the risky race for a coronavirus treatment.
Biotech stocks are in the spotlight in 2020, with the race to develop testing, treatment and a vaccine for Covid-19 driving rapid growth.
The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.
Growth is on a different track now, and here are some great ideas for stocks to buy to ride the momentum.
Investors looking for the safety of large-cap stocks alongside impressive growth should consider these five investments.
The stock charts of CAG, VRTX and HFC are poised to end the trading week in pivotal situations. Here's what you should know about each.
Here we take a closer look at five stocks with bullish calls from Goldman Sachs. As you will see, each of these stocks shows over 20% upside potential from current levels.
The stock charts of FTI, VRTX and STZ are knocking on the doors of major moves, even if the broad market isn't.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
The stock charts of HollyFrontier, Activision Blizzard and Vertex Pharmaceuticals are poised to end the trading week in a pivotal situation.
Even in these unstable times, there are still gems to be found. And these are 10 of the hottest stocks on the Street, complete with "strong buy" analyst ratings and some compelling growth drivers.
Stock charts of VRTX, NKTR and SYMC are going to end the trading week knocking on the door of major moves.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
One of the best mutual funds last year was the T. Rowe Price Health Sciences Fund. Here are 7 healthcare stocks to buy from its holdings.
Put these fast-growing stocks on your radar, if not in your portfolio, as your best shot at overcoming the market's summertime blues.
The market volatility isn't all bad! Now investors can find stocks to buy at killer entry points --determined by the Street's stop analysts.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader